Abemaciclib
- Generic Name
- Abemaciclib
- Brand Names
- Verzenio, Verzenios
- Drug Type
- Small Molecule
- Chemical Formula
- C27H32F2N8
- CAS Number
- 1231929-97-7
- Unique Ingredient Identifier
- 60UAB198HK
- Background
Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the treatment of HR-positive and HER2-negative a...
- Indication
适应症为:⑴单药治疗接受过内分泌疗法和化疗后疾病进展的 ER+/HER2-晚期或转移性乳腺癌；⑵或联合氟维司群，二线治疗接受过内分泌疗法后疾病进展的 ER+/HER2-晚期或转移性乳腺癌；⑶联合芳香酶抑制剂作为 ER+/HER2-绝经后女性晚期或转移性乳腺癌的初始内分泌疗法。
- Associated Conditions
- HR+, HER2-, Advanced Breast Cancer, Early Hormone Receptor Positive, HER2/Neu Negative Node Positive Breast Cancer, Metastatic HR + HER2 - breast cancer
- Associated Therapies
- -
Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.
- First Posted Date
- 2021-04-21
- Last Posted Date
- 2021-04-21
- Lead Sponsor
- Blokhin's Russian Cancer Research Center
- Target Recruit Count
- 1000
- Registration Number
- NCT04852081
- Locations
- 🇷🇺
N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russian Federation
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
- First Posted Date
- 2021-03-17
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 510
- Registration Number
- NCT04802759
- Locations
- 🇺🇸
Regional Cancer Care Associates LLC (RCCA) - Freehold Location, Freehold, New Jersey, United States
🇺🇸Regional Cancer Care Associates LLC ? Howell Division, Howell, New Jersey, United States
🇺🇸Levine Cancer Institute, Charlotte, North Carolina, United States
Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study
- Conditions
- Interventions
- First Posted Date
- 2021-03-17
- Last Posted Date
- 2023-05-10
- Lead Sponsor
- Peter MacCallum Cancer Centre, Australia
- Target Recruit Count
- 3
- Registration Number
- NCT04801966
- Locations
- 🇦🇺
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer
- First Posted Date
- 2021-03-10
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Criterium, Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT04791384
- Locations
- 🇺🇸
Cancer Care Northwest, Spokane Valley, Washington, United States
🇺🇸Duke Cancer Center, Durham, North Carolina, United States
🇺🇸University of Colorado, Aurora, Colorado, United States
Abemaciclib With or Without Atezolizumab for mCRPC
- Conditions
- Interventions
- First Posted Date
- 2021-02-12
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 75
- Registration Number
- NCT04751929
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-02-12
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 111
- Registration Number
- NCT04752332
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
🇨🇳Hainan Cancer Hospital, Haikou, Hainan, China
🇨🇳Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China
Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas
- First Posted Date
- 2021-02-11
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 55
- Registration Number
- NCT04750928
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
A Study of Abemaciclib in Indian Women With Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-01-13
- Last Posted Date
- 2023-11-24
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 200
- Registration Number
- NCT04707196
- Locations
- 🇮🇳
Nirmal Hospital Pvt Ltd., Surat, Gujarat, India
🇮🇳Meditrina Institute of Medical Sciences, Nagpur, Maharashtra, India
🇮🇳Rajiv Gandhi Cancer Institute And Research Centre, New Delhi, Delhi, India
Abemaciclib in Combination With Endocrine Therapy as First Line Therapy in Metastatic Breast Cancer Patients
- Conditions
- First Posted Date
- 2020-12-23
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- Technical University of Munich
- Target Recruit Count
- 120
- Registration Number
- NCT04681768
- Locations
- 🇩🇪
Klinikum rechts der Isar der TU München, Klinik und Poliklinik für Frauenheilkunde, Munich, Germany
Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer
- First Posted Date
- 2020-11-18
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 42
- Registration Number
- NCT04633239
- Locations
- 🇺🇸
University of Kansas Hospital-Indian Creek Campus, Overland Park, Kansas, United States
🇺🇸Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.